

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China NT Pharma Group Company Limited**

**中國泰凌醫藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 01011)

### **PROFIT WARNING**

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company and potential investors that based on a preliminary review of the Group’s unaudited management accounts and the information currently available to the Board, the Board currently estimates that the Group will likely record a loss for the year ended 31 December 2013.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that based on a preliminary review of the Group’s unaudited management accounts and the information currently available to the Board, the Board currently estimates that the Group will likely record a loss for the year ended 31 December 2013. The loss is mainly attributed to the Group’s business restructuring measures introduced in 2012 which involved the exiting from its vaccine and pharmaceutical supply chain business, the downsizing of its vaccine sales and promotion team as well as the termination of its over-the-counter promotion business and several dermatological products. As a result, the Group may incur further impairment charges for account receivables and inventories in relation to the terminated businesses, which will likely lead to a loss for the year ended 31 December 2013.

As the Group’s final results for the year ended 31 December 2013 are not yet available, the information contained in this announcement represents only a preliminary assessment made by the Board based on the information made available to it as at the date hereof and such information or figures have neither been audited nor reviewed by the Company’s auditors. The actual results of the Group for the year ended 31 December 2013 may be different from

what is disclosed herein. Shareholders and potential investors should read carefully the annual results announcement of the Company for the year ended 31 December 2013 which is expected to be published before the end of March 2014.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**China NT Pharma Group Company Limited**  
**Ng Tit**  
*Chairman*

Hong Kong, 17 January 2014

*As at the date of this announcement, the executive director of the Company is Mr. Ng Tit; the non-executive directors of the Company are Ms. Chin Yu, Dr. Qian Wei, Mr. Wang Fan and Mr. Hung Leung; and the independent non-executive directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.*